Can open-source R&D reinvigorate drug research?

  title={Can open-source R\&D reinvigorate drug research?},
  author={Bernard H. Munos},
  journal={Nature Reviews Drug Discovery},
  • B. Munos
  • Published 1 September 2006
  • Biology
  • Nature Reviews Drug Discovery
The low number of novel therapeutics approved by the US FDA in recent years continues to cause great concern about productivity and declining innovation. Can open-source drug research and development, using principles pioneered by the highly successful open-source software movement, help revive the industry? 

Is Open Science the Future of Drug Development?

This perspective argues that while open science poses some risks—which include the management of collaboration and the protection of proprietary data—these strategies are, in many cases, the more efficient and ethical way to conduct biomedical research.

Open Source Drug Discovery: Finding a Niche (or Maybe Several)

Despite their novelty and importance, open source methods have been largely been limited to software. However, scholars have long suggested that it would be logical to organize at least one other

Is open innovation the way forward for big pharma?

The current, fully integrated business model of large pharmaceutical companies is increasingly considered to be unsustainable, and so new approaches that engage large and small companies, governments

Pharmaceutical Research and Development: A Key Informant Assessment of Whether an “Open-Science” Model Could Improve Clinical Research in Terms of Quality and Efficiency

  • T. King
  • Political Science, Medicine
  • 2013
All articles were reviewed and included if they contained directly collected or imputed data on pharmaceutical development costs or were in English and were published from 1980 to 2011.

Lessons from 60 years of pharmaceutical innovation

  • B. Munos
  • Political Science, Biology
    Nature Reviews Drug Discovery
  • 2009
Analysis of the record of pharmaceutical innovation by analysing data on the companies that introduced the ∼1,200 new drugs that have been approved by the FDA since 1950 shows that the new-drug output from pharmaceutical companies in this period has essentially been constant, and remains so despite the attempts to increase it.

The impact of open IP platforms on IP-strategy norms in Life Sciences

A case study was conducted of the Innovative Medicines Initiative, CAMBIA Biological Open Source (BiOS) and the Medicines for Malaria Venture to assess the impact that such platforms exert on corporate IP-strategies.

Open science is a research accelerator.

An open-source approach to the problem of producing an off-patent drug in enantiopure form serves as an example of how academic and industrial researchers can join forces to make new scientific

Open Access Could Transform Drug Discovery: A Case Study of JQ1

JQ1 serves as a test case to evidence that open access drug discovery can be an economic model that potentially improves efficiency and cost of drug discovery and its subsequent commercialization, and counter the notion that openAccess drug discovery would leak commercial intellectual property.

Bio-Business in Brief: A Case for New Drugs at Generic Prices from India

The authors propose a hypothetical organization that brings drugs to market by working with a network of academic and corporate partners, and primarily working in India, and in this model new drugs would be available at generic prices from day one.

Open innovation: An opportunity for Pharmerging countries to close the technology gap?

The pharmaceutical industry is entering a critical phase in its history, with decliningprofits and patent cliffs fallouts awaiting their former blockbuster drugs. Several hypotheseshave been



The case for open-source software in drug discovery.

  • W. Delano
  • Computer Science
    Drug discovery today
  • 2005

Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships

The focus on virtual drug discovery and development as operationalized through public–private partnerships brings many advantages, as well as scientific and managerial challenges.

Finding Cures for Tropical Diseases: Is Open Source an Answer?

The Tropical Disease Initiative will be a Web-based, community- wide effort where scientists from the public and private sectors join together to discover new treatments

The Open Source Biotechnology Movement: Is it Patent Misuse?

Fledgling efforts exist to establish open-source projects in biotechnology. Following copyleft, participants agree that advances in the technology must remain as openly available as the original

Open and Collaborative Research: A New Model for Biomedicine

It is argued that open and collaborative biomedical research represents a promising experiment, not only has it produced software and genomic data that is usable, but the resulting public domain status for this software and data may reduce access and transaction cost problems for follow-on innovators.

Technology Licensing to Non-Traditional Partners

The commercialization of technologies arising from university research depends on the ability of technology managers to find and contract with appropriate development partners. Substantial investment

Creating a Tradition of Biomedical Research

Library of Congress Cataloging-in-Publication Data Creating a tradition of biomedical research: contributions to the history of the Rockefeller University / edited by Darwin H. Stapleton. p. cm.

Open-source software: not quite endsville.